Genentech Inc. will invest more than $285 million in the expansion of its biologics manufacturing facilities in Vacaville and Oceanside, CA.
The expansion in Solano County east of the San Francisco Bay Area and Oceanside in northern San Diego County will result in the addition of more than 250 new jobs at facilities over the next four years, bringing the total number of Genentech manufacturing jobs in California to close to 3,000, said Ian Clark, CEO of South San Francisco-based Genentech.
The company a member of the Roche Group, now employs 10,000 people in California.
The expansion of Genentech’s biologics manufacturing will enable the hiring of skilled workers ranging from technicians to scientists and engineers.
"California has always had an impressive skilled workforce that has allowed Genentech to hire diverse and talented individuals in various disciplines," Clark said. "In recent years California has made great strides toward improving the business environment for life sciences innovation and incentivizing manufacturing. We are committed to working with the state to continue this positive progress and make California an even better place to grow the industry."
Genentech has manufacturing facilities in South San Francisco, Vacaville, and Oceanside, as well as Hillsboro, OR, producing medicines for the treatment of cancer, rheumatoid arthritis and asthma, among other diseases.
When the expansion is complete, Genentech’s Vacaville facility will not only be the largest producer of biologic medicines for the Roche Group, but also the largest biotech manufacturing facility in the world.